George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMTFB.L Regulatory News (MTFB)

  • There is currently no data for MTFB

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Exercise of Warrants

15 May 2020 07:00

RNS Number : 9759M
Motif Bio PLC
15 May 2020
 

 

Motif Bio plc

("Motif Bio" or the "Company")

 

Exercise of Warrants

 

Motif Bio plc (AIM: MTFB), which has been reclassified as an AIM Rule 15 cash shell, announces that it has received notification from a warrant holder to exercise warrants representing 7,142,857 ordinary shares of 0.01p each ("Ordinary Shares") in the Company for total consideration of £48,571.43. The exercise price of all warrants was 0.68p per warrant.

 

Application has been made for the 7,142,857 new Ordinary Shares to be admitted to trading on AIM ("Admission"), which is expected to occur at 8.00 a.m. on 20 May 2020. The new Ordinary Shares will rank pari passu with the existing Ordinary Shares. The Company does not hold any Ordinary Shares in treasury.

 

Following Admission, and further to the announcement made on 5 May 2020, and for the purposes of the Disclosure Guidance and Transparency Rules, the Company's total issued share capital will consist of 654,991,023 Ordinary Shares. Shareholders may use this figure as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the issued share capital of the Company.

 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

 

For further information please contact:

 

 

Motif Bio plc

 

ir@motifbio.com

Jonathan Gold (President and Chief Business Officer)

 

 

 

SP Angel Corporate Finance LLP (NOMAD & BROKER)

+44 (0)20 3470 0470

David Hignell/Caroline Rowe (Corporate Finance)

 

Vadim Alexandre/Abigail Wayne (Sales & Broking)

 

 

 

Walbrook PR Ltd. (UK FINANCIAL PR & IR)

+44 (0)20 7933 8780

Paul McManus/ Lianne Cawthorne

motifbio@walbrookpr.com

 

 

Forward-Looking Statements

When used in this Press Release, the words or phrases "intends," "anticipates," "expected to be" or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks and uncertainties including, but not limited to, changes in economic conditions in the Company's market area, changes in policies by regulatory agencies, fluctuations in interest rates, competition that could cause actual results to differ materially from historical earnings and those presently anticipated or projected, and other risks described in the Company's filings with the Securities and Exchange Commission. The Company cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. The Company advises readers that the factors listed above could affect the Company's financial performance and could cause the Company's actual results for future periods to differ materially from any opinions or statements expressed with respect to future periods in any current statements. The Company does not undertake, and specifically disclaims any obligation, to publicly release the result of any revision which may be made to any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
IOESFEFMLESSEFI
Date   Source Headline
22nd Jul 20154:32 pmRNSFDA QIDP Designation
22nd Jul 20157:00 amRNSFinal condition of £22m placing satisfied
20th Jul 20157:00 amRNSExercise of Options
17th Jul 20157:00 amRNSFDA QIDP Designation for Iclaprim for HABP
15th Jul 20157:00 amRNSNew Addition to Scientific Advisory Board
10th Jul 20153:29 pmRNSExercise of Options
10th Jul 20151:37 pmRNSResult of General Meeting
23rd Jun 20158:47 amRNSPartner Company raises £22 million
23rd Jun 20157:00 amRNSPlacing to raise £22 million and Change of Adviser
9th Jun 20157:00 amRNSAudited Non-Statutory Financial Statements
4th Jun 20154:41 pmRNSSecond Price Monitoring Extn
4th Jun 20154:35 pmRNSPrice Monitoring Extension
1st Jun 20157:00 amRNSMotif partners with Leading Global CRO
28th May 20157:00 amRNSFDA Meeting Minutes Confirming Iclaprim Phase III
12th May 20157:01 amRNSMOTIF SELECTED TO PRESENT AT BIOTECH EVENT
7th May 20157:00 amRNSFunding Strategy Update
15th Apr 20157:01 amRNSFDA Results
15th Apr 20157:00 amRNSFDA agree to enter clinical development programme
2nd Apr 20157:00 amRNSFirst Day of Dealings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.